Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors

Phase 1

Completed

• Conditions: Cervical Cancer; Uterine Cancer; HEENT Cancer; RECTUM; Renal Cancer; CERVIX UTERI NOS
• Interventions: Radiation: 124I-Iodo-Azomycin Galacto-Pyranoside

• Registration Number: NCT00588276
• Lead Sponsor: Memorial Sloan Kettering Cancer Center

Brief Summary

The purpose of this study is to evaluate low oxygen areas called hypoxia within the tumor. These low oxygen areas are thought to be the reason why tumors are more resistant to radiation treatment. A tracer is an extremely small quantity of a substance. Tracer to which radioactivity has been attached may be used to "trace" events in the body. A tracer called iodo-azomycin galactopyranoside (or \*IAZGP) appears to be able to detect low oxygen areas within tumor.

Radioactive iodine in this molecule can be detected by an imaging technique called a PET scan. This present study involves obtaining three scans using this new imaging technique. The goal of carrying out many scans is to determine which scan will best show any areas in your tumor that may have low levels of oxygen.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-06
• Study First Submitted: 2007-12-22
• Study First Submitted QC: 2007-12-22
• Study First Posted: 2008-01-08
• Primary Completion: 2012-06
• Study Completion: 2012-06
• Status Verified: 2015-12
• Last Update Submitted: 2015-12-23
• Last Update Posted: 2015-12-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

• Patients must have locally advanced cancer as determined by currently accepted diagnostic work-up, including CT/MR/US.
• KPS >70%.
• Patients must be > or equal to 18 years of age.

Read More

Exclusion Criteria

• Patients will be excluded from the study if they fulfill any of the following criteria:
• Patients with abnormal baseline thyroid function tests, or any thyroid disorder including but not limited to hypothyroidism and thyroiditis. Patients with thyroid cancer who have had a thyroidectomy are not excluded.
• Patients who are pregnant or lactating.
• Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study.
• Patients who cannot tolerate being in the PET scanner for the duration of the study.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
1	124I-Iodo-Azomycin Galacto-Pyranoside	Patients will receive 124IAZGP(124I-Iodo-Azomycin Galacto-Pyranoside).

Primary Outcome Measures

Name	Time	Method
To describe imaging findings in human cancer with the new hypoxia tracer 124IAZGP and PET/CT	at least once at approximately 6 hours and/or 24 hours after radiotracer administration.
To evaluate the biodistribution of 124IAZGP using serial PET imaging and to estimate blood radioactivity	5, 15, 30 and 60 minutes after 124IAZGP, and before and after each. A 5-mL volume of blood will be drawn at each sampling time point.
To obtain further human dosimetry data with 124IAZGP	2 years

Trial Locations

Locations (1)

Memorial Sloan-Kettering Cancer Center; 🇺🇸 New York, New York, United States